Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,106
Employees15,106
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,106
Employees15,106

REGN Key Statistics

Market cap
60.18B
Market cap60.18B
Price-Earnings ratio
14.01
Price-Earnings ratio14.01
Dividend yield
0.47%
Dividend yield0.47%
Average volume
899.79K
Average volume899.79K
High today
$570.67
High today$570.67
Low today
$555.81
Low today$555.81
Open price
$555.81
Open price$555.81
Volume
868.12K
Volume868.12K
52 Week high
$1,170.58
52 Week high$1,170.58
52 Week low
$476.49
52 Week low$476.49

REGN News

Benzinga 2d
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy

Regeneron Pharmaceuticals, Inc. REGN on Tuesday announced five-year follow-up results on overall survival (OS) from the Phase 3 EMPOWER-Lung 3 trial of Libtayo...

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy
TipRanks 2d
Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron, with a price target of $640.00. Elevate Your Investing Str...

TipRanks 2d
Regeneron announces follow-up results on Phase 3 EMPOWER-Lung 3 trial

Regeneron (REGN) Pharmaceuticals announced five-year follow-up results on overall survival from the Phase 3 EMPOWER-Lung 3 trial, which evaluated Libtayo plus p...

Analyst ratings

79%

of 28 ratings
Buy
78.6%
Hold
17.9%
Sell
3.6%

More REGN News

TipRanks 2d
Sandoz reaches agreement with Regeneron over patent litigation

Sandoz (SDZNY) announced that it has reached an agreement with Regeneron Pharmaceuticals (REGN), to resolve all patent disputes between the two companies relati...

Benzinga 3d
What's Happening With Regeneron Pharmaceuticals Stock On Monday?

Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their...

What's Happening With Regeneron Pharmaceuticals Stock On Monday?
TipRanks 3d
Regeneron announces results of Phase 3 trials on allergen-blocking antibodies

Regeneron (REGN) announced results evaluating its nvestigational allergen-blocking antibodies in allergen-challenge Phase 3 trials in adults with moderate-to-se...

TipRanks 4d
Regeneron’s Innovative Cancer Study: A Potential Game-Changer for Advanced Tumors

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

TipRanks 4d
Regeneron Advances Melanoma Treatment with Long-term Study Update

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

TipRanks 4d
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for Genetic Disorders

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

TipRanks 4d
Regeneron’s Phase 2 Melanoma Study: A Potential Game-Changer in Cancer Treatment

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 5...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.